These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sorafenib rechalenge in metastatic renal cell carcinoma. Porta C; Paglino C; Imarisio I BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769 [No Abstract] [Full Text] [Related]
5. Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. Lekili M; Muezzinoglu T; Nese N; Temeltas G J Chin Med Assoc; 2010 May; 73(5):262-4. PubMed ID: 20685594 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Mizutani Y Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634 [TBL] [Abstract][Full Text] [Related]
7. Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients. Tomita Y Int J Urol; 2010 Sep; 17(9):815-6. PubMed ID: 20727052 [No Abstract] [Full Text] [Related]
8. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299 [TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. Raspollini MR Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159 [No Abstract] [Full Text] [Related]
10. Sorafenib [corrected] in kidney cancer. Escudier B Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603 [No Abstract] [Full Text] [Related]
11. [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. Morimoto H; Tsuzaka Y; Kaneko T; Matsushima H; Homma Y Gan To Kagaku Ryoho; 2010 Oct; 37(10):2007-10. PubMed ID: 20948275 [TBL] [Abstract][Full Text] [Related]
12. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694 [TBL] [Abstract][Full Text] [Related]
13. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305 [No Abstract] [Full Text] [Related]
14. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U Oncology; 2009; 76(5):350-4. PubMed ID: 19321976 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166 [TBL] [Abstract][Full Text] [Related]
17. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676 [TBL] [Abstract][Full Text] [Related]
18. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Massard C; Zonierek J; Gross-Goupil M; Fizazi K; Szczylik C; Escudier B Ann Oncol; 2010 May; 21(5):1027-31. PubMed ID: 19850637 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735 [TBL] [Abstract][Full Text] [Related]